Bitcoin (btc)$63,470.00↓ 1.28%
Ethereum (eth)$1,799.06↑ 0.02%
Tether (usdt)$0.999218↑ 0.01%
BNB (bnb)$586.63↓ 0.65%
USDC (usdc)$0.999594↑ 0.01%
XRP (xrp)$0.97382↓ 0.34%
Solana (sol)$74.66↓ 0.16%
TRON (trx)$0.311317↑ 1.12%
Figure Heloc (figr_heloc)$1.023↑ 1.59%
Hyperliquid (hype)$67.53↓ 1.29%
Zcash (zec)$929.74↓ 2.35%
Monero (xmr)$502.33↓ 0.43%
Dogecoin (doge)$0.059203↑ 0.12%
LEO Token (leo)$9.30↑ 0.03%
USDS (usds)$0.999969↑ 0.01%
Bitcoin (btc)$63,470.00↓ 1.28%
Ethereum (eth)$1,799.06↑ 0.02%
Tether (usdt)$0.999218↑ 0.01%
BNB (bnb)$586.63↓ 0.65%
USDC (usdc)$0.999594↑ 0.01%
XRP (xrp)$0.97382↓ 0.34%
Solana (sol)$74.66↓ 0.16%
TRON (trx)$0.311317↑ 1.12%
Figure Heloc (figr_heloc)$1.023↑ 1.59%
Hyperliquid (hype)$67.53↓ 1.29%
Zcash (zec)$929.74↓ 2.35%
Monero (xmr)$502.33↓ 0.43%
Dogecoin (doge)$0.059203↑ 0.12%
LEO Token (leo)$9.30↑ 0.03%
USDS (usds)$0.999969↑ 0.01%
Verge Genomics and Ferrer Collaborate to Advance ALS Drug Candidate VRG50635 Globally – Draper Decentralized – 9.19.24

Stream unavailable

Verge Genomics and Ferrer Collaborate to Advance ALS Drug Candidate VRG50635 Globally – Draper Decentralized – 9.19.24

Published September 19, 2024

Verge Genomics and Ferrer have partnered to co-develop VRG50635, a promising AI-discovered drug for ALS treatment. Ferrer will develop and commercialize the drug in select global markets, while Verge retains U.S. rights as it advances through clinical trials.